Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment.

Eleonora Vitali Ilena BoemiGiulia TarantolaSara PicciniAlessandro ZerbiGiulia VeronesiRoberto BaldelliGherardo MazziottiValeria SmiroldoElisabetta LavezziAnna SpadaGiovanna MantovaniAndrea Gerardo Lania

Published in: Cancers (2020)

Considering the promising effects of the everolimus and metformin combination in NET cells, our results provide a rationale for its use in NET patients.

Keyphrases

neuroendocrine tumors
end stage renal disease
induced apoptosis
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
cell cycle arrest
oxidative stress
cell proliferation
signaling pathway